Obermatt

Flags

Earnings warning

Galapagos

AEX:GLPG · BE0003818359
BiotechnologyMedium

360

76
EV / EBIT100
Price / Owner Earnings12
Owner Earnings Yield98
Dividend Yield1
Price/Sales5
Price/Book90
Return on Capital92
Cash Return on Capital96
Return on Equity96
EBIT Margin100
Gross Profitability74
Accruals23
Owner Earnings Margin98
Sales growth1
Profit growth1
Reinvestment13
Price momentum58
Debt load100
Refinancing49
Debt Payback100
Liquidity100
Analyst ratings1
Opinion Changes50
Price Target Upside14
Market mood33
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Galapagos generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryBelgium
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeENXTAM
Founded1999
Employees666
Websiteglpg.com
ISINBE0003818359
Last UpdateApr 2, 2026
Themes
InflammationHematologyImmunologyRheumatologyStem Cell TherapyDermatologyOncology

Description

Lakefront Biotherapeutics NV is a biotechnology company. The company combines deal making expertise with capital to identify, acquire, and advance promising opportunities that drive value for patients and shareholders. Applying a modality-agnostic a…

Analysis

Quality compounder

Lakefront Biotherapeutics NV earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 3.2×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
42
2026

All-time high

42

Jun 2026

All-time low

4

Mar 2026

Average rank

23

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
5
Price/Earnings
100
Price/Book
90
Dividend Yield
1
Value (overall)
53

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Galapagos with its peers
SOPHiA GENETICS
NSQ:SOPH
52
CountrySwitzerland
IndustryHealth Care Technology
SizeSmall
Full Stock Analysis →
Elekta
STO:EKTA B
42
CountrySweden
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Wix.com
NSQ:WIX
35
CountryIsrael
IndustryIT Services
SizeMedium
Full Stock Analysis →
Netcompany Group
CPH:NETC
8
CountryDenmark
IndustryIT Services
SizeMedium
Full Stock Analysis →
Opera
NSQ:OPRA
93
CountryNorway
IndustrySoftware
SizeMedium
Full Stock Analysis →
Planisware
PAR:PLNW
69
CountryFrance
IndustrySoftware
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →